B Bethea Established Member 56 minutes ago #141 An anti-PACAP monoclonal antibody (mAb) has been successful for treating migraine in a phase 2b trial and they are now setting up a phase 3 trial.
An anti-PACAP monoclonal antibody (mAb) has been successful for treating migraine in a phase 2b trial and they are now setting up a phase 3 trial.
